GHENT, Belgium, 28 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from BlackRock, Inc. on 26 February 2018.
BlackRock, Inc. (taking into account the holdings of its subsidiary undertakings) notified Ablynx that it has upward crossed the 3% threshold of voting rights held through financial instruments since 23 February 2018 and now holds a total of 3,035,133 voting securities of Ablynx, representing 4.04% of the current 75,065,990 outstanding voting rights of Ablynx.
The notification contains the following information:
- Reason for the notification: acquisition or disposal of financial instruments that are treated as voting securities
- Notification by: a parent undertaking or a controlling person
- Persons subject to the notification requirement:
|Name||Address (for legal entities)|
|BlackRock, Inc.||55 East 52nd Street, New York, NY, 10055, U.S.A.|
|BlackRock (Netherlands) B.V.||Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands|
|BlackRock Advisors (UK) Limited||12 Throgmorton Avenue, London, EC2N 2DL, U.K.|
|BlackRock Advisors, LLC||100 Bellevue Parkway, Wilmington, DE, 19809, U.S.A.|
|BlackRock Asset Management Canada Limited||161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada|
|BlackRock Asset Management Deutschland AG||Max-Joseph-Straße 6, Munich, 80333, Germany|
|BlackRock Financial Management, Inc.||55 East 52nd Street, New York, NY, 10055, U.S.A.|
|BlackRock Fund Advisors||400 Howard Street, San Francisco, CA, 94105, U.S.A.|
|BlackRock Institutional Trust Company, National Association||400 Howard Street, San Francisco, CA, 94105, U.S.A.|
|BlackRock Investment Management (Australia) Limited||Level 37, Chifley Tower, 2 Chifley Square, Sydney NSW 2000 Australia|
|BlackRock Investment Management, LLC||1 University Square Drive, Princeton, NJ, 8540, U.S.A.|
|BlackRock Japan Co., Ltd.||1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan|
- Transaction date: 23 February 2018
- Threshold that is crossed: 3% of voting rights held through financial instruments
- Denominator: 75,065,990
- Details of the notification:
|Name of select subsidiaries of BlackRock||% of voting rights||% of voting rights held through financial instruments*||Total of both|
|BlackRock (Netherlands) B.V.||0.01%||0.01%|
|BlackRock Advisors (UK) Limited||0.17%||0.63% 1||0.80%|
|BlackRock Asset Management Canada Limited||0.00%||0.01% 1||0.01%|
|BlackRock Asset Management Deutschland AG||0.28%||0.28%|
|BlackRock Fund Advisors||0.00%||0.80% 1||0.80%|
|BlackRock Institutional Trust Company, National Association||0.21%||0.30% 1 / 0.11% 2||0.62%|
|BlackRock Advisors, LLC||0.20% 2||0.20%|
|BlackRock Financial Management, Inc.||0.57% 2||0.57%|
|BlackRock Investment Management, LLC||0.75% 2||0.75%|
* Type of financial instrument: 1'Securities lent' and 2'Contract for Difference'
- Chain of controlled undertakings through which the holding is effectively being held: Please see the full chain of control in the Transparency Notification.
- Additional information: The disclosure obligation arose due to voting rights through financial instruments for BlackRock, Inc. going above 3%
A full version of the transparency notification is available on Ablynx website, under the section Investors.
The Articles of the Association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
Follow us on Twitter @AblynxABLX
Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
Joele Frank, Wilkinson Brimmer Katcher
Dan Katcher or Joseph Sala
t: +1 212-355-4449